Skip to main content
Equibles
FDMT logo

FDMT · 4D Molecular Therapeutics, Inc. · Metrics

Track FDMT — free

Use FDMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FDMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.93 +0.97 (+8.11%) At close · Oct 28
Russell 2000 member Rebalance outlook locked
Market Cap
$863.27M
Shares
72.18M
Volume · Oct 28 1.19M Avg daily vol (3M) 996.07K

FDMT metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.93
Market cap
$863.27M

Price action

20 metrics
Price change (1W)
-8.7%
Price change (30D)
-17.9%
Price change (3M)
+21.4%
Price change (6M)
+27.0%
Price change (YTD)
+59.5%
Price change (1Y)
-2.5%
Trailing year
Price change (5Y)
-61.8%
52-week high
$16.76
52-week low
$7.19
Change from 52-week high
-28.6%
Change from 52-week low
+66.3%
Annualized volatility
75.6%
Annualized volatility (3M)
73.8%
Beta
1.7
RSI (14D)
43.8
Price vs SMA 50
-14.0%
Price vs SMA 200
+10.7%
Avg volume (3M)
987,439
Relative volume
1.2
Average dollar volume
$13.47M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
72.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.7×
reciprocal yield 17.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
9.4×
reciprocal yield 10.7%
P / book
2.1
reciprocal yield 47.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-870.6×
EV / revenue historical average (5Y)
-870.6×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-08-08

Profitability

9 metrics
Gross margin
—
Operating margin
-214.2%
Trailing 12 months
Net margin
-194.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$197.12M
Net income (TTM)
−$179.18M
Trailing 12 months
Diluted EPS (TTM)
$-2.63
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-3.05
Capital expenditures per diluted share (TTM)
$0.06
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.38

Growth

11 metrics
Revenue growth YoY
+25,106.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$92.01M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.6%
Year over year · more shares
Revenue CAGR (3Y)
+200.9%
Revenue CAGR (5Y)
+44.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-44.0%
Return on assets
-36.4%
Debt / equity
0.0
Current ratio
8.0
EBITDA (TTM)
−$192.09M
Free cash flow (TTM)
—
Quick ratio
8.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$341.75M
Latest balance sheet
Cash & equivalents
$70.37M
Total assets
$492.62M
Total debt
$19.59M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$156.07M
Capital expenditures (TTM)
$3.42M
R&D (TTM)
$240.31M
SG&A (TTM)
—
Stock compensation (TTM)
$20.41M
R&D / revenue
261.2%
Stock compensation / revenue
22.2%

Ownership (13F)

9 metrics
13F filers
159
13F filer change QoQ
+6
Institutional ownership
81.1%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+18.6%
Holder tenure
10.2
Price vs estimated holder cost
+4.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.0%

Short interest

3 metrics
Short interest
16.0%
Latest settlement · 12.0 days to cover
Days to cover
12.0d
Short-squeeze score
79 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.14M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1650648 CUSIP 35104E100 13F (30d) 20 filings 20 filers Visit website Investor relations